CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.

William Buller,Lalit Pallan,Teresa Chu,Leila Khoja

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）

引用 0|浏览1

暂无评分

摘要

Toxicity across CDK4/6 inhibitors overlaps. The optimal sequence of therapies post CDK4/6 inhibitors remains unknown but rechallenge with an alternative agent is possible.

查看译文

关键词

CDK4/6 inhibitor,Metastatic breast cancer,toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要